Clinical-stage biotech developing antibody-drug conjugates for cancer.
| Date | Round | Amount |
|---|---|---|
| Nov 2024 | Series B Adcendo closed an oversubscribed $135M Series B led by TCGX to advance its antibody-drug conjugate pipeline through clinical development. | $135M |
| Jun 2024 | Series A Copenhagen biotech Adcendo raised a €16M Series A extension led by Dawn Biopharma, bringing its Series A total to €98M. | $17.3M |
| Apr 2023 | Series A Copenhagen biotech Adcendo raised an additional EUR31M, extending its Series A to EUR82M, led by Pontifax. | $33.5M |